Tasquinimod and paquinimod blocked the S100a8/a9‐Tlr4‐Nfκb signaling pathway, improved renal function, and reduced mortality, and also decreased inflammatory monocytes infiltration, ameliorated kidney injury phenotype, and prevented long‐term renal fibrosis. The gene discussed is IGKV1D-22; the disease is renal fibrosis.